EPS for Mustang Bio, Inc. (MBIO) Expected At $-0.25

July 14, 2018 - By Tina Thibodeau

Analysts expect Mustang Bio, Inc. (NASDAQ:MBIO) to report $-0.25 EPS on August, 13.After having $-0.24 EPS previously, Mustang Bio, Inc.’s analysts see 4.17 % EPS growth. The stock increased 0.67% or $0.05 during the last trading session, reaching $7.49. About 86,312 shares traded. Mustang Bio, Inc. (NASDAQ:MBIO) has 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T cell technology. The company has market cap of $201.67 million. The Company’s lead programs include MB-101 for the treatment of brain cancer that is in Phase I trials; and MB-102, a therapeutic agent in acute myeloid leukemia, which is in Phase I trials. It currently has negative earnings. Mustang Bio, Inc. has a research collaboration agreement with Beth Israel Deaconess Medical Center for the development of CRISPR/Cas9-enhanced CAR T therapies for the treatment of cancer; and a license agreement with Harvard University.

More important recent Mustang Bio, Inc. (NASDAQ:MBIO) news were published by: Nasdaq.com which released: “Mustang Bio Added to Russell 2000®, 3000® and Microcap® Indexes” on June 25, 2018, also Nasdaq.com published article titled: “Mustang Bio Announces Opening of CAR T Cell Therapy Manufacturing Facility in Worcester, Mass.”, Gurufocus.com published: “Small-Cap Biotechs Developing Novel Gene Therapies Could Become Targets of Big Pharma” on June 20, 2018. More interesting news about Mustang Bio, Inc. (NASDAQ:MBIO) was released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: FDA Greenlights Tandem Diabetes’ Insulin Pump, More IPOs On Tap” with publication date: June 22, 2018.

Mustang Bio, Inc. (NASDAQ:MBIO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: